Breaking Down the Barriers to Utilizing Long-Acting Injectable Antipsychotics for Schizophrenia Management

Schizophrenia management remains one of the greatest challenges facing psychiatrists and other clinicians who care for these individuals. Despite profound burdens on the individual, family, and society, schizophrenia is still under-recognized and undertreated with more than half of persons receiving suboptimal treatment or no mental health interventions at all. In this session, expert faculty will review clinician- and patient-related barriers and how to overcome those barriers. They will also examine how clinicians can effectively create personalized treatment options for patients when administering LAIs and the importance of patient-clinician communication.

This activity has been supported through an independent educational grant from Teva Pharmaceuticals.

Long-Acting Injectables 360 (LAI360) is a new initiative, part of the Psychiatry and Behavioral Health Learning Network, intended to educate clinicians on clinical data of LAI pharmacodynamics and pharmacokinetic, improved adherence strategies, and patient-centric communication techniques. LAI360 Medical Resource Center has the latest clinical updates in LAI-based treatment of schizophrenia, including videos highlighting best practices and motivational interviewing techniques.